Pneumococcal vaccine in children and young adults with chronic renal disease

Fuchshuber, Arno; Kühnemund, O; Keuth, B.; Lütticken, Rudolf; Michalk, Dietrich; Querfeld, Uwe

doi:10.1093/ndt/11.3.468

Cited by 47 publications

(47 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, children with steroid-resistant nephrotic syndrome have been observed to have significantly lower levels of anti-pneumococcal antibodies to numerous specific capsular types as compared with healthy children (41). It is interesting that revaccination of children and young adults who have kidney disease (both CKD and ESRD) who lose protective titers 1 yr after initial vaccination has been associated with a lower response rate and more rapid loss of protective antibody titers as compared with the initial vaccination (42).…”

Section: Vaccinationmentioning

confidence: 99%

Epidemiology of Acute Infections among Patients with Chronic Kidney Disease

Dalrymple¹,

Go²

2008

Clinical Journal of the American Society of Nephrology

202

183

View full text Add to dashboard Cite

The objectives of this review were (1) to review recent literature on the rates, risk factors, and outcomes of infections in patients who had chronic kidney disease (CKD) and did or did not require renal replacement therapy; (2) to review literature on the efficacy and use of selected vaccines for patients with CKD; and (3) to outline a research framework for examining key issues regarding infections in patients with CKD. Infection-related hospitalizations contribute substantially to excess morbidity and mortality in patients with ESRD, and infection is the second leading cause of death in this population. Patients who have CKD and do not require renal replacement therapy seem to be at higher risk for infection compared with patients without CKD; however, data about patients who have CKD and do not require dialysis therapy are very limited. Numerous factors potentially predispose patients with CKD to infection: advanced age, presence of coexisting illnesses, vaccine hyporesponsiveness, immunosuppressive therapy, uremia, dialysis access, and the dialysis procedure. Targeted vaccination seems to have variable efficacy in the setting of CKD and is generally underused in this population. In conclusion, infection is a primary issue when caring for patients who receive maintenance dialysis. Very limited data exist about the rates, risk factors, and outcomes of infection in patients who have CKD and do not require dialysis. Future research is needed to delineate accurately the epidemiology of infections in these populations and to develop effective preventive strategies across the spectrum of CKD severity.

show abstract

Section: Vaccinationmentioning

confidence: 99%

Epidemiology of Acute Infections among Patients with Chronic Kidney Disease

Dalrymple¹,

Go²

2008

Clinical Journal of the American Society of Nephrology

202

183

View full text Add to dashboard Cite

show abstract

“…[5] In addition, it has been demonstrated that protection against diphtheria and the immune response to Td vaccine in hemodialysis (HD) patients is poor (i.e., a seroconversion rate of 37%). [16,17] It is also noteworthy to mention that the response to tetanus and diphtheria vaccinations is highly related (p < 0.04). [1] Although several studies have focused on the protection of HD patients against infections by vaccination, no guidelines are yet available for preventive care in patients with CKD, including the use of vaccines such as the Td booster vaccine.…”

Section: Introductionmentioning

confidence: 97%

A Study on the Protection of Hemodialysis Patients Against Diphtheria and Tetanus

2009

View full text Add to dashboard Cite

Patients with end stage renal disease suffer from a high incidence of infectious diseases believed to be related to their impaired immune system. To determine the antitetanus and antidiphtheria IgG antibody levels in Iranian hemodialysis patients with end stage renal disease, as well as its association with sex, age, hemoglobin, zinc serum level, serum albumin, duration of dialysis, number of dialysis per week, dialysis adequacy, erythropoietin or iron supplements such as venofer, body mass index (BMI), and underlying renal disorder, we conducted a crosssectional study on a total of 112 hemodialysis patients with end stage renal disorder (60 male, 52 female ) and 36 healthy individuals in the control group (14 male, 22 female). The patients and the control group received no antitetanus or antidiphtheria vaccine or immunoglobulin in the year prior to the investigation. The serum antitetanus and antidiphtheria IgG antibody levels were measured using the ELISA method. We found out that only 16% of our hemodialysis patients were immune to diphtheria (19% of the control group), and this rate for tetanus was 24% (48.2% in the healthy control). Except for the hemodialysis duration, none of the mentioned factors seemed to affect immunity. We conclude that in our study, the level of the antitetanus IgG antibody (unlike the antidiphtheria IgG antibody level) is significantly different among the hemodialysis patients, the chronic hemodialysis patients, and the control group.

show abstract

“…However, hyporesponsiveness to several vaccines has been described in children with CKD (9)(10)(11)(12)(13)(14)(15)(16). In this study, we examine the immunogenicity of the quadrivalent HPV vaccine in girls with CKD, ESRD, or kidney transplants.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD

Nelson

Neu

Abraham

et al. 2016

CJASN

View full text Add to dashboard Cite

Background and objectives There is a disproportionate burden of human papillomavirus (HPV) -related genital tract disease in patients with CKD and kidney transplantation; therefore, the potential effect of the quadrivalent HPV vaccine (Gardasil; Merck GmbH, Darmstadt, Germany) is profound. Immune abnormalities associated with CKD and immunosuppression may prevent optimal vaccine response. Our objective was to determine antibody response to the HPV vaccine in adolescent girls with CKD.Design, setting, participants, & measurements This cohort study conducted from 2008 to 2012 included 57 girls aged 9-21 years old with CKD (n=25), on dialysis (n=9), or with status postkidney transplantation (n=23) who received the standard three-dose vaccine series of the HPV vaccine recruited from two pediatric nephrology clinics. Antibody levels to HPV genotypes 6, 11, 16, and 18 were measured before vaccine dose 1 (baseline), ,12 months after vaccine dose 3 (blood draw 2), and $12 months after vaccine dose 3 (blood draw 3). Seropositivity was defined as antibody level above an established threshold for each HPV genotype. Not all participants completed three blood draws.Results Antibody response to all four HPV genotypes was 100% in the CKD and dialysis groups with samples drawn at ,12 and $12 months after dose 3 of the HPV vaccine. Among patients with transplants, the percentages of patients achieving seropositivity were significantly lower at blood draw 2 for HPV genotypes 6 (63.6%; P=0.003), 11 (63.6%; P=0.003), and 18 (72.7%; P=0.02) and blood draw 3 for HPV genotypes 6 (62.5%; P=0.02), 11 (50%; P=0.001), 16 (75%; P=0.04), and 18 (50%; P=0.001).Conclusions Antibody response to the quadrivalent recombinant HPV vaccine was robust and sustained in girls and young women with CKD and on dialysis. A less robust response to the vaccine was observed among those with a kidney transplant. Additional study is needed to determine if vaccination before kidney transplantation or an alternative vaccination regimen would benefit transplant recipients.

show abstract

Pneumococcal vaccine in children and young adults with chronic renal disease

Cited by 47 publications

References 24 publications

Epidemiology of Acute Infections among Patients with Chronic Kidney Disease

Epidemiology of Acute Infections among Patients with Chronic Kidney Disease

A Study on the Protection of Hemodialysis Patients Against Diphtheria and Tetanus

Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD

Contact Info

Product

Resources

About